Information  X 
Enter a valid email address

BioPharma Credit PLC (BPCR)

  Print      Mail a friend

Wednesday 19 June, 2019

BioPharma Credit PLC

Result of AGM

RNS Number : 8204C
BioPharma Credit PLC
19 June 2019
 

BIOPHARMA CREDIT PLC

 

(THE "COMPANY")

 

 

RESULT OF ANNUAL GENERAL MEETING

 

 

The Company is pleased to announce that, at the Annual General Meeting held today, all resolutions were passed on a show of hands.

 

The proxy votes received in relation to these resolutions were as follows:

 

Resolutions

 

Votes

For

 

%

Votes Against

 

%

Votes at Chairman's Discretion

Votes Withheld

1: To receive and accept the annual report and financial statements

 

  895,570,264

100

0

0

0

0

2: To approve the Directors' Remuneration Report

 

895,570,264

100

0

0

0

0

3: To re-elect Jeremy Sillem as a Director

 

895,570,264

100

0

0

0

0

4: To re-elect Colin Bond as a Director

 

895,570,264

100

0

0

0

0

5: To re-elect Duncan Budge as a Director

 

895,570,264

100

0

0

0

0

6: To re-elect Harry Hyman as a Director

 

866,249,863

96.73

29,320,401

3.27

0

0

7: To elect Stephanie Léouzon as a Director

 

895,570,264

100

0

0

0

0

8: To re-appoint Pricewaterhouse Coopers LLP as Auditor to the Company

 

895,570,264

100

0

0

0

0

9: To authorise the Directors to determine the remuneration of the Auditor

 

895,570,264

100

0

0

0

0

10: To approve the Company's dividend payment policy

 

895,570,264

100

0

0

0

0

11: To authorise the Company to make market purchases

of ordinary shares

 

790,025,298

89.98

88,000,000

10.02

0

17,544,966

12: To authorise the Company to hold general meetings

on 14 clear days' notice

 

895,570,264

100

0

0

0

0

 

A copy of resolutions 11 and 12 has been submitted to the National Storage Mechanism and will shortly be available for inspection at www.morningstar.co.uk/uk/NSM

 

19 June 2019

 

 

Enquiries:

 

Buchanan

David Rydell / Mark Court / Jamie Hooper / Henry Wilson

+44 (0) 20 7466 5000

[email protected]

 

 

Notes to Editors:

 

BioPharma Credit PLC is London's only listed specialist debt investor to the life sciences industry and joined the LSE on 27 March 2017. The Company seeks to provide long-term shareholder returns, principally in the form of sustainable income distributions from exposure to the life sciences industry. The Company seeks to achieve this objective primarily through investments in debt assets secured by royalties or other cash flows derived from the sales of approved life sciences products.

 

 

LEI: 213800AV55PYXAS7SY24

 

 


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.
 
END
 
 
RAGSFFFWUFUSEFM

a d v e r t i s e m e n t